Cohort study to quantify the risk of glaucoma with intravitreal VEGF inhibitors (bevacizumab, ranibizumab, aflibercept)

ENCePP Code of conduct

No

Data sources

• Data source(s):
  ARS Toscana
• Data source(s), other:
  ARS
• Data sources (types):
  Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No